Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on innovation and believes in their long-term growth potential. However, they did not provide specific guidance for future quarters.
Management highlighted ongoing investment in innovation and product development.
They expressed confidence in their long-term growth strategy despite current challenges.
The earnings report indicates that 10X Genomics is still in a development phase, as reflected in the negative EPS. Despite missing on EPS, the stock rose by 2.26%, likely due to positive sentiment around management's focus on innovation. Investors may be optimistic about the company's long-term prospects, even without specific guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSOLIDATED EDISON
Nov 4, 2019